Relieve the intense itch of chronic prurigo with old and new therapies

Patients with chronic prurigo (CPG) experience intense itching leading to constant scratching, resultant lesions and, often, poor sleep and life quality. First-line therapies include emollients, topical corticosteroids and calcineurin inhibitors and ultraviolet therapies, with systemic agents including immunomodulators and neurological agents also suggested. In randomized controlled trials, dupilumab and nemolizumab both improved CPG itch and lesions and have subsequently become the first treatments to receive approval for prurigo nodularis (the most common subtype of CPG). Other emerging treatments, including vixarelimab, and Janus kinase inhibitors (abrocitinib and povorcitinib), show early promise in CPG.